Targeted therapeutics against pathogen-associated proteins often lead to drug resistance. Targeting host proteins is an alternative to overcoming drug resistance and improving outcomes for infectious diseases. However, discovering and developing targets for human-pathogen protein interactions is laborious, time consuming, and costly. Engineered cell libraries address the growing need to streamline targeted therapeutic development workflows by enabling parallel screening of large numbers of host protein candidates.

Download this case study from Synthego to learn how engineered cell libraries accelerate target validation from virus-host protein interactions.

Sponsored by